ATR and neoplasm: Given its characteristic immunogenicity, G1 cell cycle checkpoint deficiencies and associated sensitivity to DNA-damaging agents, we propose that MCC is a highly appealing tumor to test whether ATR inhibition can overcome resistance to PD-1 pathway blockade.